Hartford Investment Management Co. lifted its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,551 shares of the biopharmaceutical company’s stock after buying an additional 66 shares during the quarter. Hartford Investment Management Co.’s holdings in Regeneron Pharmaceuticals were worth $2,676,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Smithfield Trust Co. purchased a new stake in Regeneron Pharmaceuticals in the first quarter valued at approximately $27,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $29,000. Citizens Financial Group Inc RI purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $30,000. Accurate Investment Solutions Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $31,000. Finally, Thor Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter worth approximately $32,000. 66.97% of the stock is currently owned by hedge funds and other institutional investors.
Several research analysts have recently issued reports on REGN shares. UBS Group cut their target price on shares of Regeneron Pharmaceuticals from $480.00 to $440.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Morgan Stanley cut their target price on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating on the stock in a report on Wednesday, May 8th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, July 19th. Argus cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. Finally, BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals to $344.00 and set a “market perform” rating on the stock in a report on Wednesday, August 7th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $398.25.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.60 by $0.69. The business had revenue of $1.93 billion during the quarter, compared to the consensus estimate of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period in the prior year, the company posted $5.45 EPS. On average, analysts forecast that Regeneron Pharmaceuticals Inc will post 19.22 EPS for the current year.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.